Advertisement

Topics

Deciphera grants Zai exclusive ripretinib rights in Greater China

15:40 EDT 13 Jun 2019 | Elsevier Business Intelligence

Deciphera Pharmaceuticals Inc. granted Zai Lab Ltd. exclusive development and commercialization rights for its gastrointestin...

Original Article: Deciphera grants Zai exclusive ripretinib rights in Greater China

NEXT ARTICLE

More From BioPortfolio on "Deciphera grants Zai exclusive ripretinib rights in Greater China"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...